Nuvation Bio (NUVB) Rockets to 3‑Year High as Wall Street Lifts Price Targets on IBTROZI Momentum – November 20, 2025
Nuvation Bio Inc. has become one of the hottest tickers in biotech this week. On November 20, 2025, NUVB is trading near a three‑year high after a powerful earnings beat, accelerating uptake of its lung‑cancer drug IBTROZI™ (taletrectinib), and a wave of bullish analyst upgrades that continue to roll in today. Seeking Alpha+2Trefis+2 At the time of writing, Nuvation Bio shares trade around $7.15, up roughly 49% today, with an intraday high of $7.21 and heavy trading volume, extending a massive multi‑day rally. Quiver Quantitative Key Takeaways for November 20, 2025 NUVB Stock: From Under‑the‑Radar Biotech to Market Standout The